AlphaVax
BioTech/Drugs - Durham, NC, US
AlphaVax Details
The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.
Website:
alphavax.com
Employees:
100 - 249
HQ:
800-658-2849
Location:
Durham, NC, US
Revenue:
20 - 50 Million
AlphaVax Technologies
Email Providers
Outlook
Social Sharing
AddThis
Fonts
Google Font API
Hosting
GoDaddy Hosting
Other
Google Maps